

PATENT Attorney Docket No.: 07873.0002

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

in re Application of:	)	
Solco WALLE SCHALM et al.	)	
Serial No.: 09/689,637	)	Group Art Unit: 1614
Filed: October 13, 2000	)	Examiner: Unassigned
or: COMBINED HEPATITIS B TREATMENT		

Assistant Commissioner for Patents Washington, D.C. 20231

Sir:

## **Preliminary Amendment**

Before examining this application, please amend the claims as follows:

## In the claims:

Please cancel claims 1-10 and re-write them as new claims 11-20 as follows:.

- --11. A method of treating a human patient infected with hepatitis B virus, which comprises administering to the patient both a nucleoside analogue and interferon-α during a period of at least 26 weeks.
- 12. A method according to claim 11, wherein the nucleoside analogue and interferon-α are administered at intervals ranging from daily to weekly.
- 13. A method according to claim 11, wherein the nucleoside analogue and interferon- $\alpha$  are both administered during a period of at least 30 weeks.
- 14. A method according to claim 11, wherein the period is preceded by a period wherein one of a nucleoside analogue and interferon- $\alpha$  is administered.
- 15. A method according to claim 11, wherein the period is followed by a period wherein one of a nucleoside analogue and interferon-α is administered.
- 16. A method according to claim 11, wherein the nucleoside analogue is lamivudine, adefovir or entecavir.